公开(公告)号：US12112853B2

公开(公告)日：2024-10-08

申请号：US17611997

申请日：2020-05-29

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES ,  UNIVERSITE PARIS-SACLAY ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS—

发明人： Irène Buvat

IPC分类号： G06N3/08 ,  G06T7/00 ,  G16H20/10 ,  G16H50/30

CPC分类号： G16H50/30 ,  G06T7/0014 ,  G16H20/10 ,  G06T2207/10104 ,  G06T2207/30096

摘要： The present invention relates to a method for assisting with lymphoma prognosis. The prognosis of therapeutic response of patients with lymphoma is difficult. Based on a study of advanced stage DLBCL patients, the inventors showed that medical imaging such as 18F-FDG-PET/CT can provide a prognostic radiomic signature combining metrics reflecting tumor dissemination and tumor burden. In another aspect, the invention relates to a computer software comprising instructions to implement at least a part of a method according to the invention. In yet another aspect, the invention relates to a computer-readable non-transient recording medium on which a software is registered to implement a method according to the invention.

公开(公告)号：US12102974B2

公开(公告)日：2024-10-01

申请号：US17416225

申请日：2019-12-20

申请人： Paris Sciences et Lettres ,  Centre National de la Recherche Scientifique (CNRS) ,  Sorbonne Universite ,  Ecole Nationale Superieure de Chimie de Paris ,  Univ Paris XIII Paris-Nord Villetaneuse

发明人： Vincent Piepiora ,  Stéphanie Ognier ,  Simeon Cavadias ,  Xavier Duten ,  Michael Tatoulian ,  Maria Elena Galvez-Parruca ,  Patrick Da Costa

IPC分类号： B01J19/08 ,  B01J8/06 ,  B01J19/24 ,  B01J23/755 ,  C07C1/04 ,  C07C1/12 ,  C07C29/152 ,  C07C29/156 ,  H05H1/24

CPC分类号： B01J19/088 ,  B01J8/06 ,  B01J19/242 ,  B01J23/755 ,  C07C1/041 ,  C07C1/12 ,  C07C29/152 ,  C07C29/156 ,  H05H1/2406 ,  H05H1/2431 ,  H05H1/245 ,  B01J2219/0809 ,  B01J2219/0815 ,  B01J2219/0828 ,  B01J2219/083 ,  B01J2219/0841 ,  B01J2219/0849 ,  B01J2219/0871 ,  B01J2219/0875 ,  B01J2219/0892 ,  B01J2219/0896 ,  B01J2219/182 ,  B01J2219/1943 ,  B01J2219/2408 ,  B01J2219/2411 ,  B01J2219/243 ,  C07C2523/755 ,  H05H2245/15

摘要： The present invention concerns a reactor for the conversion of carbon dioxide or carbon monoxide into hydrocarbon and/or alcohol comprising a support made from an electrically and thermally conductive material, forming the wall or walls of at least one longitudinal channel that passes through the support and also acting as the cathode of the reactor, at least one wire electrode forming an anode of the reactor, and extending within each longitudinal channel, and being arranged at a distance from the wall or walls of the longitudinal channel, each wire electrode optionally being covered with an electrically insulating layer along the part of the wire electrode extending within the longitudinal channel, a catalyst capable of catalysing a conversion reaction for the conversion of carbon dioxide or carbon monoxide into hydrocarbon and/or alcohol, the catalyst being situated between the wire electrode and the wall or walls of each longitudinal channel.

公开(公告)号：US20240317890A1

公开(公告)日：2024-09-26

申请号：US18269615

申请日：2022-01-14

申请人： INSTITUT CURIE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - ,  HONING BIOSCIENCES

发明人： Franck PEREZ ,  Sandrine MOUTEL ,  Zélia GOUVEIA

IPC分类号： C07K16/32 ,  A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  G01N33/574

CPC分类号： C07K16/32 ,  C07K14/7051 ,  C07K14/70578 ,  G01N33/57484 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03

摘要： The present invention relates to humanized HER2 single domain antibodies and variants thereof and their use in therapy and for cancer diagnosis. The invention most particularly proposes chimeric antigen receptors including said humanized HER2 sdAb in their antigen binding domain and their use in cancer cell therapy.

公开(公告)号：US20240317812A1

公开(公告)日：2024-09-26

申请号：US18629579

申请日：2024-04-08

申请人： Centre National de la Recherche Scientifique (CNRS) ,  Université Paris-Saclay

发明人： Aurélie Albertini ,  Yves Gaudin ,  Hèlène Raux ,  Laura Belot ,  Jovan Nikolic

IPC分类号： C07K14/005 ,  C12N7/00

CPC分类号： C07K14/005 ,  C12N7/00 ,  C12N2760/20222 ,  C12N2760/20232 ,  C12N2760/20245 ,  C12N2760/20262

摘要： The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and/or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

公开(公告)号：US20240316005A1

公开(公告)日：2024-09-26

申请号：US18575431

申请日：2022-07-04

申请人： INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  UNIVERSITÉ DE BORDEAUX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITÉ COTE D'AZUR

发明人： Andreas BIKFALVI ,  Wilfried SOULEYREAU ,  Lindsay COOLEY ,  Marie NIKOLSKI ,  Justine RUDEWICZ ,  Gilles PAGES ,  Maeva DUFIES

IPC分类号： A61K31/404 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C12Q1/6886

CPC分类号： A61K31/404 ,  A61K39/3955 ,  A61P35/00 ,  C07K16/2818 ,  C12Q1/6886 ,  C07K2317/21 ,  C12Q2600/118 ,  C12Q2600/158

摘要： Renal Cell Carcinoma (RCC) is difficult to treat with 5-year survival rate of 10% in metastatic patients. Main reasons of therapy failure are lack of validated biomarkers and scarce knowledge of the biological processes occurring during RCC progression. Thus, the investigation of mechanisms regulating RCC progression is fundamental to improve RCC therapy. In order to identify molecular markers and gene processes involved in the steps of RCC progression, the inventors generated several cell lines of higher aggressiveness by serially passaging mouse renal cancer RENCA cells in mice and, concomitantly, performed functional genomics analysis of the cells. Multiple cell lines depicting the major steps of tumor progression (including primary tumor growth, survival in the blood circulation and metastatic spread) were generated and analyzed by large-scale transcriptome, genome and methylome analyses. Importantly, transcriptome analysis revealed distinct signatures of tumor aggressiveness which were validated in the TCGA-KIRC cohort. The signatures are particularly suitable for determining the survival time of the patients and predicting response to the therapies.

公开(公告)号：US20240301512A1

公开(公告)日：2024-09-12

申请号：US18263014

申请日：2022-01-28

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE ,  UNIVERSITE TOULOUSE III – PAUL SABATIER

发明人： Jacques AMAR ,  David BRASSAT ,  Béatrice PIGNOLET

IPC分类号： C12Q1/689 ,  C07K16/28 ,  C12Q1/6883

CPC分类号： C12Q1/689 ,  C07K16/2842 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/172

摘要： Natalizumab a monoclonal antibody is associated with the risk of progressive multifocal leukoencephalopathy (PML), an infection caused by the John Cunningham (JC) virus. The inventors explored the hypothesis that bacteria should be involved in the onset of PML in connection to the HLA-DR haplotype in multiple sclerosis (MS) patients. Thus 625 MS patients starting Natalizumab therapy from the BIONAT study were followed prospectively. Among those patients, 12 developed a PML. Outside the BIONAT cohort, we included nine additional MS patients with PML who had been referred to our center. For each patient, blood metagenomics sequencing and sequencing-based typing for HLA-DRB1*15:01 ancestral haplotype were determined. HLA-DRB1*15:01 haplotype carriers show a protection against PML (p=0.03). Among blood taxa, at genus level, Phyllobacterium was only significantly associated in HLA-DRB1*15:01 haplotype carriers with an inflammatory marker (p 2% have an odds ratio of 4.55 (95% confidence intervals 1.82-11.37; p=0.001) of developing or having PML under NTZ treatment. In conclusion, the inventors showed a relation between the HLA-DRB1*15:01 haplotype, the circulating microbiota and the risk of PML. The interaction between blood microbiota and the HLA-DRB1*15:01 haplotype may play a role in the virulence of the viruses.

公开(公告)号：US20240294864A1

公开(公告)日：2024-09-05

申请号：US18044891

申请日：2021-09-13

申请人： IMMUNRISE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

发明人： Lionel NAVARRO ,  Jerome ZERVUDACKI ,  Magali CHARVIN ,  Antonio Emidio FORTUNATO

IPC分类号： C12N1/12 ,  A01N63/60 ,  A01N65/03 ,  A01P1/00 ,  C12N15/11

CPC分类号： C12N1/12 ,  A01N63/60 ,  A01N65/03 ,  A01P1/00 ,  C12N15/111 ,  C12N2310/14 ,  C12N2330/50

摘要： The invention relates to a novel method to produce small RNAs targeting virulence factors, essential genes and/or antimicrobial resistance genes of phytopathogens. More specifically, the invention involves the expression of exogenous RNA interference (RNAi) precursor(s) in Chlorella cells, which in turn express and release Extracellular Vesicle (EV)-embedded antimicrobial small RNAs. These EVs can be collected from the cell-free medium of Chlorella cultures, and further concentrated and purified for biocontrol applications. Importantly, Chlorella EVs protect small RNAs from ribonuclease-mediated digestion, indicating that these lipid-based particles not only act as natural vectors of small RNAs towards pathogenic cells, but also presumably limit their degradation in the environment. The invention can thus likely be used to reduce the pathogenicity and growth of a wide range of pathogens or, potentially, to enhance beneficial effects and growth of plant-associated symbiotic and commensal microbes. Furthermore, because the integrity of Chlorella EV-embedded antimicrobial siRNAs remains unaltered when produced in photobioreactors, and when stored frozen, this method has the potential to be further exploited for the industrialization and manufacturing of a novel generation of microalgae-based biologicals.

公开(公告)号：US20240277801A1

公开(公告)日：2024-08-22

申请号：US18569392

申请日：2022-06-30

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITÉ DE TOURS FRANÇOIS RABELAIS ,  UNIVERSITÉ DE LILLE ,  INSTITUT PASTEUR DE LILLE ,  CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE

发明人： Nathalie HEUZE VOURC'H ,  Alexie MAYOR ,  Jean-Claude SIRARD

IPC分类号： A61K38/16 ,  A61K9/00 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26

CPC分类号： A61K38/164 ,  A61K9/0078 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26

摘要： The present invention arises from a formulation study in order to define the best excipients including buffer, surfactant, sugar and amino acid to stabilize Flagellin during mesh-nebulization. One of the key factors in stabilising proteins is determining the optimal pH and buffer system to provide adequate solubility and stability and avoid aggregate formation during the aerosolization process. Different formulation have been assayed in order to obtain a stable and soluble aerosol composition comprising flagellin polypeptide in particular considering the choice of the buffering agent, the surfactant and the pH of the liquid formulation comprising the flagellin polypeptide in order to maintain the activity of the flagellin after the aerosolization process. Accordingly, the present invention relates to an aerosol composition comprising droplets comprising a liquid formulation, wherein the liquid formulation comprises a flagellin polypeptide, a buffer (acetate and/or phosphate) and a surfactant (polysorbate). The aerosol composition of the present invention is suitable for the treatment of lung bacterial infections.

公开(公告)号：US20240262680A1

公开(公告)日：2024-08-08

申请号：US18562689

申请日：2022-05-20

申请人： SILMACH ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITE DE FRANCHE-COMTE

发明人： Marc Sworowski ,  Cédric Vuillemin ,  Haythem AMEUR ,  Gilles BOURBON ,  Patrice LE MOAL

IPC分类号： B81B7/00

CPC分类号： B81B7/008 ,  B81B2201/033 ,  B81B2203/0136 ,  B81B2203/0172 ,  B81B2203/056

摘要： The invention relates to a method for controlling a microelectromechanical system by means of an electrical control signal alternating between a maximum voltage value (Vmax) and a minimum voltage value (Vmin), wherein, during the transition from the maximum voltage value (Vmax) to the minimum voltage value (Vmin), the value of the voltage of the electrical control signal monotonously decreases from the maximum voltage value (Vmax) to the minimum voltage value (Vmin), which signal comprising, in sequential order:



a first slope between the maximum voltage value (Vmax) and a first voltage threshold value (Vend),
a second slope, having a lower absolute value than the first slope, between the first voltage threshold value (Vend) and a second voltage threshold value (Vstart), and
a third slope, having a higher absolute value than the second slope, between the second voltage threshold value (Vstart) and the minimum voltage value (Vmin).

公开(公告)号：US20240228546A9

公开(公告)日：2024-07-11

申请号：US18130375

申请日：2023-04-03

申请人： Institut National De La Sante Et De La Recherche Medicale (INSERM) ,  Centre National De La Recherche Scientifique (CNRS) ,  Ecole Normale Superieure De Lyon ,  Universite Claude Bernard Lyon 1

发明人： Théophile OHLMANN ,  Philippe MANGEOT ,  Emiliano RICCI

IPC分类号： C07K14/005 ,  C12N7/00 ,  C12N9/22 ,  C12N15/10 ,  C12N15/113

CPC分类号： C07K14/005 ,  C12N7/00 ,  C12N9/22 ,  C12N15/102 ,  C12N15/113 ,  C07K2319/00 ,  C07K2319/43 ,  C07K2319/50 ,  C12N2310/20 ,  C12N2740/10023 ,  C12N2740/10042 ,  C12N2740/13023 ,  C12N2740/13042 ,  C12N2800/80

摘要： The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.